OBJECTIVES & ACCREDITATION
TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
TYPE OF ACTIVITY Live Activity; Application
Educational Objectives At the conclusion of this activity, all participants should be able to: • Discuss strategies to improve the knowledge, skills or performance of the healthcare team;
Session I: Defining Targets, Goals, and Thresholds for Treatment
• Define lipid treatment goals for patients with dyslipidemia. • Describe the various measurements of low-density lipoprotein (LDL-C) and the effect on clinical decisions. • Review the evidence for benefit from LDL-C lowering therapies. • Evaluate clinical scenarios where additional lipid testing may inform clinical decisions.
Session II: Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia
• Outline the impact of various diets on short and long-term weight loss. • Utilize effective diet and lifestyle strategies for dyslipidemia management. • Assess the impact of increasing physical activity on Atherosclerotic Cardiovascular Disease (ASCVD) risk.
Clinical Pearls for the Lipidologist
• Discuss practical strategies for the optimal preventive therapy in diabetes. • Discuss practical strategies for evaluating blood pressure in the clinic. • Discuss practical non-prescription treatment strategies for ASCVD prevention.
Session III: Emerging Science in Clinical Lipidology
• Review the practical implications of current publications to the evaluation and management of patients with dyslipidemia. • Assess the implications of recent ASCVD outcomes data for the clinical management of patients with dyslipidemia. • Evaluate current and novel biomarkers and their impact on Cardiovascular (CV) risk detection and management.
Session IV: Lipoprotein(a): The Neglected CVD Risk Factor
• Review current recommendations for Lipoprotein(a) (Lp(a)) screening. • Determine possible association between Lp(a) levels and the development of aortic stenosis. • Define treatment options to reduce residual ASCVD risk.
NLA Special Session: Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management
• Identify genetic triglyceride disorders, including Familial Combined Hyperlipidemia, Hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS), in clinical practice. • Review current management recommendations and emerging therapeutic interventions for improving the outcomes in patients with FCS. • Implement a team-based approach to the clinical management of FCS, effectively involving lipidologists, gastroenterologists, nurses, pharmacists, dietitians, lifestyle educators and other healthcare professionals.
Session V: Complex Cases with the “Aces”
• Discuss complex lipid case management for clinical lipidologists.
Session VI: Plaque Biology and Implications for Clinical Practice
• Review the pathogenesis of atherosclerotic plaque development and progression. • Discuss the roles of imaging in cardiovascular disease risk evaluation. • Review the atherosclerotic plague effects of various lipid treatment strategies.
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is October 26, 2018.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
COMMERCIAL SUPPORT
This activity is supported by educational funding provided by Akcea Therapeutics and Amgen.
CREDIT DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
CME/CE credit provided by the National Lipid Association
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement The National Lipid Association designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.50 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-18-019-L01-P (Application) This Activity has been approved for 12.50 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education
Nursing The maximum number of hours awarded for this CE activity is 12.4 contact hours.
For the advanced practice nurse, this activity has 2.0 contact hours of pharmacotherapy content.
DISCLOSURE INFORMATION
Lori A. Alexander, MSHS, RD, CLS, FNLA Has nothing to disclose.
Karen E. Aspry, MD, MS, FNLA Contracted Research: Amgen, Akcea
Jan N. Basile, MD Advisory Board: Medtronic, ReCor, Up-to-Date Speakers Bureau: Arbor, Janssen, Novartis
Michael J. Blaha, MD, MPH Advisory Board: Akcea, Amgen, Novo Nordisk, Sanofi/Regeneron Contracted Research: Aetna Foundation, Amgen
Marc P. Bonaca, MD, MPH Consultant: Amgen, Aralez, AstraZeneca, Bayer, Janssen, Merck, Sanofi Contracted Research: Amgen, AstraZeneca, MedImmune, Merck, Pfizer
Alan S. Brown, MD, FNLA Advisory Board: Akcea, Amgen, AstraZeneca, Merck & Co., Inc., Pfizer Speaker: Amarin, Regeneron, Sanofi
Kathleen Hawke Byrne, CRNP, BSN, MSN Advisory Board: Amgen
Christopher P. Cannon, MD Consultant: Alnylam, Amarin, Amgen, Arisaph, Astra Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, Takeda Contracted Research: Amgen, Arisaph, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Takeda
Karen Collins, MS, RDN, CDN, FAND Consultant: The Wellness Network Speaker: Dairy West
Sergio Fazio, MD, PhD, FNLA Advisory Board: Aegerion, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi Consultant: Aegerion, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi
Keith C. Ferdinand, MD, FNLA Consultant: Amgen, Boehringer-Ingelheim, Quantum Genomics, Novartis, Sanofi
Edward A. Fisher, MD, PhD, FNLA Consultant: Amgen Speakers Bureau: Merck
Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA Has nothing to disclose.
Edward A. Gill, MD, FNLA Has nothing to disclose.
Anne C. Goldberg, MD, FACP, FNLA Consultant: OptumRX , Sanofi/ Regeneron Contracted Research: Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, ISIS (IONIS), Merck & Co., Inc., Pfizer, Regeneron, Regeneron/ sanofi-aventis Scholarly Contributions: Merck & Co., Inc.
Antonio M. Gotto, MD, DPhil, FNLA Advisory Board: Vatera Capital, Spruceview Board of Directors: Esperion Pharmaceuticals, Ionis Pharmaceuticals Consultant: Kowa, Merck, Pfizer Medical Advisor: Stuart & Stevenson
John R. Guyton, MD, FNLA Contracted Research: Amarin, Amgen, Sanofi, Regeneron Speaker: Amgen
Linda C. Hemphill, MD, FNLA Contracted Research: Ionis, Regeneron/ Sanofi Consultant: Amgen, Regeneron
Elizabeth Jackson, MSN, ACNS- BS, CLS, FNLA Advisory Board: sanofi-aventis u.s. and Regeneron Pharmaceuticals Speakers Bureau: sanofi-aventis u.s. and Regeneron Pharmaceuticals
Peter H. Jones, MD, FNLA Consultant: Amgen, Merck & Co., Inc., sanofi-aventis U.S., and Regeneron Pharmaceuticals Speaker: Merck & Co., Inc.
Dean G. Karalis, MD, FNLA Consultant: Sanofi/ Regeneron Speakers Bureau: Sanofi/ Regeneron
Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA Has nothing to disclose.
Alice H. Lichtenstein, DSc, MS Has nothing to disclose.
Seth S. Martin, MD, MHS Advisory Board: Akcea, Amgen, Quest Diagnostics, Sanofi/ Regeneron
Jan L. McAlister, DNP, CLS, FNLA Advisory Board: Amgen, Sanofi/ Regeneron Speakers Bureau: Akcea, Amgen, Sanofi/ Regeneron
Kellie H. McLain, ANP-BC, CLS Has nothing to disclose.
Pamela B. Morris, MD, FNLA Advisory Board: Aegerion, AstraZeneca, Regeneron/ Sanofi
Joseph J. Saseen, PharmD, CLS, FNLA Has nothing to disclose. Vikesh K. Singh, MD, MSc TO BE PROVIDED
Daniel E. Soffer, MD, FNLA Advisory Board: Akcea Contracted Research: Akcea, Amgen, AstraZeneca, Esperion, Ionis Pharmaceuticals, Kowa, Novartis, Sanofi, Regeneron, Regenex Speakers Bureau: Sanofi
John M. Stafford, MD, PhD Has nothing to disclose.
James A. Underberg, MD, MS, FNLA Advisory Board: Akcea, Alexion Pharmaceuticals, Amgen, Regeneron, Sanofi Consultant: Amarin, Amgen Contracted Research: Aegerion Pharmaceuticals Speaker: Alexion Pharmaceuticals, Amgen, Regeneron, Sanofi, True Health Diagnostics
Anish K. Vani, MD Has nothing to disclose.
Barbara S. Wiggins, PharmD, CLS, FNLA Has nothing to disclose.
Staff Disclosures NLA Staff Has nothing to disclose.
NLA CME Committee Reviewers Christie M. Ballantyne, MD, FNLA Consultant: Abbott Laboratories, Amarin Corp., Amgen, AstraZeneca, Boehringer- Ingelheim, Eli Lilly and Company, Esperion Therapeutics, Inc., Ionis, Matinas BioPharma Holdings, Inc., Merck & Co., Inc., Novartis, Pfizer, Regeneron, Sanofi- Synthelabo, Inc. Contracted Research: Abbott Laboratories, Amarin Corp., Amgen, Inc., Esperion Therapeutics, Inc., Ionis, Novartis Pharmaceuticals, Pfizer, Regeneron, Roche Diagnostics, Sanofi- Synthelabo, Inc.
B Alan Bottenberg, DO, FACOI, FNLA Speakers Bureau- Amgen
Kathleen Hawke Byrne, CRNP, BSN, MSN Advisory Board: Amgen
Dave Dixon, PharmD, CLS, FNLA, AACC Has nothing to disclose.
Casey Elkins, DNP, NP-C, CLS, FNLA Consultant: Regeneron/ Sanofi Speaker: Regeneron/ Sanofi
Abimbola O. Farinde, PharmD Has nothing to disclose.
Edward Mark Goldenberg, MD, FNLA Speaker- Amarin, Amgen, Regeneron
Susan Halli Demeter, DNP Has nothing to disclose.
Mahmoud Adeeb Ahmad Hamdan, MD, CDE Has nothing to disclose.
Linda C. Hemphill, MD, FNLA Contracted Research: Ionis, Regeneron/ Sanofi Consultant: Amgen, Regeneron
Donald G. Lamprecht, PharmD, BCPS, CLS, FNLA Has nothing to disclose.
Pamela B. Morris, MD, FNLA Advisory Board: Aegerion, AstraZeneca, Regeneron/ Sanofi
Saleem Naina, PharmD Has nothing to disclose.
Roda Plakogiannis, PharmD, BS, BCPS, CLS, FNLA Has nothing to disclose.
Michael D. Shapiro, DO, FNLA Consultant: Akcea, Alexion, Amgen, Bracco Diagnostics, GE Healthcare, Kastle
Khalid Hasan Sheikh, MD, FNLA Speaker: Amarin, Amgen, Novartis
Scott W. Shurmur, MD, FNLA Speaker: Regeneron
Sean D. Stewart, PharmD, CLS, FNLA Has nothing to disclose.
Wayne S. Warren, MD, FNLA Speaker: Amarin, Amgen
Thomas Rhyne White, MD, FNLA Speaker: Amarin, Ionis, Janssen
Suzana D. Zamecnik, NP, CLS Has nothing to disclose.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
PERMISSIONS The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.